{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T16:55:34Z","timestamp":1756572934290},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ital J Pediatr"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>The aim of this study was to assess the cost-utility of palivizumab versus no prophylaxis in the prevention of respiratory syncytial virus infection among high-risk preterm infants.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We used and adapted a pre-existent model in which two cohorts of patients received palivizumab or no prophylaxis. The patients were followed for their expected lifetimes. The economic evaluation was conducted from the perspective of the Italian National Health Service. We considered Life-Years Gained (LYGs), Quality-Adjusted Life-Years (QALYs) and direct medical costs (pharmacological treatment, hospitalization, recurrences for wheezing, etc.). LYGs and QALYs were based on the results of a double blind cohort study with prospective follow-up and direct medical costs were based on Italian treatment patterns. Benefits and costs were discounted at 3%. Costs were assessed in 2007 Euros. Sensitivity and threshold analysis on key clinical and economic parameters were performed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Result<\/jats:title>\n            <jats:p>For the two cohorts, the expected life-years (per patient) with palivizumab versus no prophylaxis were 29.842 and 29.754 years, respectively. Quality-adjusted life years (per patient) with palivizumab were 29.202, and for no prophylaxis were 29.043. The expected cost (per patient) was \u20ac 6,244.20 with palivizumab and \u20ac 4,867.70 with no prophylaxis. We calculated for palivizumab versus no prophylaxis the incremental cost per LYG and per QALY gained. It was \u20ac 15,568.65 and \u20ac 8,676.74, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This study suggests that, compared with no prophylaxis, palivizumab is cost-effective in the prevention of respiratory syncytial virus infection among high risk preterm infants.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1824-7288-35-4","type":"journal-article","created":{"date-parts":[[2009,2,25]],"date-time":"2009-02-25T19:15:03Z","timestamp":1235589303000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants"],"prefix":"10.1186","volume":"35","author":[{"given":"Gaetano","family":"Chirico","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Ravasio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urbano","family":"Sbarigia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,2,25]]},"reference":[{"key":"9_CR1","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S0140-6736(98)10263-5","volume":"354","author":"EAF Simoes","year":"1999","unstructured":"Simoes EAF: Respiratory syncytial virus infection. Lancet. 1999, 354: 847-52.","journal-title":"Lancet"},{"key":"9_CR2","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1164\/ajrccm.161.5.9906076","volume":"161","author":"N Sigurs","year":"2000","unstructured":"Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B: Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med. 2000, 161: 1501-7.","journal-title":"Am J Respir Crit Care Med"},{"key":"9_CR3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1164\/rccm.200406-730OC","volume":"171","author":"N Sigurs","year":"2005","unstructured":"Sigurs N, Gustafsson PM, Bjarnason R, Lundberg F, Schmidt S, Sigurbergsson F, Kjellman B: Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med. 2005, 171: 137-41. 10.1164\/rccm.200406-730OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"9_CR4","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(98)10321-5","volume":"354","author":"RT Stein","year":"1999","unstructured":"Stein RT, Sherrill D, Morgan WJ, Holberg CJ, Halonen M, Taussig LM, Wright AL, Martinez FD: Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet. 1999, 354: 541-5. 10.1016\/S0140-6736(98)10321-5.","journal-title":"Lancet"},{"key":"9_CR5","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1136\/thx.2003.013391","volume":"59","author":"L Bont","year":"2004","unstructured":"Bont L, Steijn M, Van Aalderen WM, Brus F, Th Draaisma JM, Van Diemen-Steenvoorde RA, Pekelharing-Berghuis M, Kimpen JL: Seasonality of long-term wheezing following respiratory syncytial virus lower respiratory tract infection. Thorax. 2004, 59: 512-6. 10.1136\/thx.2003.013391.","journal-title":"Thorax"},{"key":"9_CR6","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/j.1399-3038.2005.00298.x","volume":"16","author":"J Henderson","year":"2005","unstructured":"Henderson J, Hilliard TN, Sherriff A, Stalker D, Al Shammari N, Thomas HM: Hospitalization for RSV bronchiolitis before 12 months of age and subsequent asthma, atopy and wheeze: a longitudinal birth cohort study. Pediatr Allergy Immunol. 2005, 16: 386-92. 10.1111\/j.1399-3038.2005.00298.x.","journal-title":"Pediatr Allergy Immunol"},{"key":"9_CR7","unstructured":"Virus Respiratorio Sinciziale: [http:\/\/www.vrsinfo.it]"},{"key":"9_CR8","doi-asserted-by":"publisher","first-page":"S150","DOI":"10.1067\/S0022-3476(03)00513-4","volume":"143","author":"JS Sampalis","year":"2003","unstructured":"Sampalis JS: Morbidity and mortality after RSV-associated hospitalizations among premature canadian infants. J Pediatr. 2003, 143: S150-S156. 10.1067\/S0022-3476(03)00513-4.","journal-title":"J Pediatr"},{"key":"9_CR9","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/ppul.20058","volume":"38","author":"M Korppi","year":"2004","unstructured":"Korppi M, Piippo-Savolainen E, Korhonen K, Remes S: Respiratory morbidity 20 years after RSV infection in infancy. Pediatr Pulmonol. 2004, 38: 155-60. 10.1002\/ppul.20058.","journal-title":"Pediatr Pulmonol"},{"key":"9_CR10","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1086\/514115","volume":"176","author":"S Johnson","year":"1997","unstructured":"Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, Dormitzer M, O'Grady J, Koenig S, Tamura JK, Woods R, Bansal G, Couchenour D, Tsao E, Hall WC, Young JF: Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 1997, 176: 1215-1224.","journal-title":"J Infect Dis"},{"key":"9_CR11","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1097\/00006454-199802000-00006","volume":"17","author":"KN Subramanian","year":"1998","unstructured":"Subramanian KN, Weisman LE, Rhodes T, Ariagno R, S\u00e1nchez PJ, Steichen J, Givner LB, Jennings TL, Top FH, Carlin D, Connor E: Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Pediatr Infect Dis J. 1998, 17: 110-115. 10.1097\/00006454-199802000-00006.","journal-title":"Pediatr Infect Dis J"},{"key":"9_CR12","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1097\/00006454-199809000-00007","volume":"17","author":"X S\u00e1ez-Llorens","year":"1998","unstructured":"S\u00e1ez-Llorens X, Casta\u00f1o E, Null D, Steichen J, S\u00e1nchez PJ, Ramilo O, Top FH, Connor E: Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Pediatr Infect Dis J. 1998, 17: 787-791. 10.1097\/00006454-199809000-00007.","journal-title":"Pediatr Infect Dis J"},{"key":"9_CR13","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1542\/peds.102.3.531","volume":"102","author":"The IMpact-RSV Study Group","year":"1998","unstructured":"The IMpact-RSV Study Group: Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998, 102: 531-537. 10.1542\/peds.102.3.531.","journal-title":"Pediatrics"},{"key":"9_CR14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jpeds.2007.02.032","volume":"151","author":"EA Simoes","year":"2007","unstructured":"Simoes EA, Groothuis JR, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick LM, Kimpen JL, Palivizumab Long-Term Respiratory Outcomes Study Group: Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr. 2007, 151: 34-42. 10.1016\/j.jpeds.2007.02.032.","journal-title":"J Pediatr"},{"issue":"2","key":"9_CR15","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/BF03320561","volume":"8","author":"R Ravasio","year":"2006","unstructured":"Ravasio R, Lucioni C, Chirico G: Costo-efficacia di palivizumab versus non profilassi nella prevenzione delle infezioni da VRS nei bambini pretermine, a diversa et\u00e0 gestazionale. PharmacoEconomics \u2013 Italian Research Articles. 2006, 8 (2): 105-117.","journal-title":"PharmacoEconomics \u2013 Italian Research Articles"},{"key":"9_CR16","first-page":"673","volume-title":"Arch Dis Child","author":"A Greenough","year":"2004","unstructured":"Greenough A, Alexander J, Burgess S, Bytham J, Chetcuti PA, Hagan J, Lenney W, Melville S, Shaw NJ, Boorman J, Coles S, Turner J, Pang F: Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection. Arch Dis Child. 2004, 673-678. 10.1136\/adc.2003.036129."},{"key":"9_CR17","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1097\/00005650-199607000-00004","volume":"34","author":"GW Torrance","year":"1996","unstructured":"Torrance GW, Feeny DH, Furlong WJ, Barr RD, Zhang Y, Wang Q: Multiattribute utility function for a comprehensive health status classification system. Medical Care. 1996, 34: 702-22. 10.1097\/00005650-199607000-00004.","journal-title":"Medical Care"},{"key":"9_CR18","unstructured":"Decreto U.A.C.\/C. n\u00b0 96\/2000. Pubblicato in Gazzetta Ufficiale n. 43 del. 2000"},{"key":"9_CR19","volume-title":"Roma","author":"Conferenza delle Regioni e Province Autonome","year":"2005","unstructured":"Conferenza delle Regioni e Province Autonome: Tariffa Unica Convenzionale per le prestazioni di assistenza ospedaliera. Regole e tariffe valide per il 2006. Roma. 2005"},{"key":"9_CR20","unstructured":"Dal Negro RW, Turco P, Canonica WG, Progetto S.I.R.I.O (Social Impact of Respiratory Integrated Outcomes): Ricerca multicentrica nazionale sui costi generati dalle malattie respiratorie, V Congresso Nazionale di Medicina Respiratoria, Milano 6\u20139 ottobre 2004, Proceedings."},{"key":"9_CR21","volume-title":"Il Pensiero Scientifico Editore","author":"MF Drummond","year":"2000","unstructured":"Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW: (Edizione italiana a cura di Fattore G, Garattini L, Lucioni C) Metodi per la valutazione economica dei programmi sanitari. Il Pensiero Scientifico Editore. 2000"},{"issue":"suppl 4","key":"9_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2165\/00019053-200422004-00003","volume":"22","author":"B Jonsson","year":"2004","unstructured":"Jonsson B: Changing health environment: the challenge to demonstrate cost-effectiveness of new compounds. Pharmacoeconomics. 2004, 22 (suppl 4): 5-10. 10.2165\/00019053-200422004-00003.","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"9_CR23","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1539-6924.1995.tb00330.x","volume":"15","author":"TO engs","year":"1995","unstructured":"engs TO, Adams ME, Pliskin JS, Safran DG, Siegel JE, Weinstein MC, Graham JD: Five-hundred life-saving interventions and theircost-effectiveness. Risk Analysis. 1995, 15 (3): 369-90. 10.1111\/j.1539-6924.1995.tb00330.x.","journal-title":"Risk Analysis"},{"issue":"11","key":"9_CR24","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.2165\/00019053-200119110-00004","volume":"19","author":"B George","year":"2001","unstructured":"George B, Harris A, Mitchell A: Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics. 2001, 19 (11): 1103-9. 10.2165\/00019053-200119110-00004.","journal-title":"Pharmacoeconomics"},{"key":"9_CR25","unstructured":"National Institute for Health and Clinical Excellence. [http:\/\/www.nice.org.uk\/]"},{"issue":"1","key":"9_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2165\/00019053-200725010-00006","volume":"25","author":"MJ Nuijten","year":"2007","unstructured":"Nuijten MJ, Wittenberg W, Lebmeier M: Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis. Pharmacoeconomics. 2007, 25 (1): 55-71. 10.2165\/00019053-200725010-00006.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"9_CR27","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1157\/13092505","volume":"65","author":"P L\u00e1zaro y de Mercado","year":"2006","unstructured":"L\u00e1zaro y de Mercado P, Figueras Aloy J, Dom\u00e9nech Mart\u00ednez E, Ech\u00e1niz Urcelay I, Closa Monasterolo R, Wood Wood MA, Fitch Warner K: The efficiency (cost-effectiveness) of palivizumab as prophylaxis against respiratory syncytial virus infection in premature infants with a gestational age of 32\u201335 weeks in Spain. Anales de Pediatria. 2006, 65 (4): 316-24. 10.1157\/13092505.","journal-title":"Anales de Pediatria"},{"issue":"10","key":"9_CR28","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1001\/archpedi.160.10.1070","volume":"160","author":"NO Elhassan","year":"2006","unstructured":"Elhassan NO, Sorbero ME, Hall CB, Stevens TP, Dick AW: Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease. Archives of Pediatrics & Adolescent Medicine. 2006, 160 (10): 1070-6. 10.1001\/archpedi.160.10.1070.","journal-title":"Archives of Pediatrics & Adolescent Medicine"},{"issue":"5","key":"9_CR29","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0091-6749(99)70075-8","volume":"104","author":"P Lozano","year":"1999","unstructured":"Lozano P, Sullivan SD, Smith DH, Weiss KB: The economic burden of asthma in US children: estimates from the National Medical Expenditure Survey. J Allergy Clin Immunol. 1999, 104 (5): 957-63. 10.1016\/S0091-6749(99)70075-8.","journal-title":"J Allergy Clin Immunol"}],"container-title":["Italian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1824-7288-35-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T23:52:22Z","timestamp":1630453942000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijponline.biomedcentral.com\/articles\/10.1186\/1824-7288-35-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,25]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["9"],"URL":"https:\/\/doi.org\/10.1186\/1824-7288-35-4","relation":{},"ISSN":["1824-7288"],"issn-type":[{"value":"1824-7288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,25]]},"assertion":[{"value":"15 October 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2009","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"4"}}